Biomerica Secures $2.23M via Private Placement at $1.60/Share, Grants B. Riley Board Seat
BMRA sits 17% above its 52-week low of $1.45.
Summary
Biomerica raised $2.23M via a private placement at $1.60/share, with B. Riley gaining a board designation right and insiders locked up for 180 days.
Key Events · Financing and Capital Events · BMRA
-
Private Placement Closed
Sold 1,393,705 shares at $1.60 per share for approximately $2.23 million in gross proceeds; closing occurred August 26, 2026.
-
B. Riley Board Designation Right
B. Riley Principal Capital may designate one board representative for as long as B. Riley Purchasers hold at least 10% of voting power.
-
Insider Lock-Ups
Directors and certain executive officers entered 180-day lock-up agreements restricting transfers of company securities.
-
Registration Rights with Penalties
Company must file a resale registration statement within 30 days and have it effective within 30 days (60 if full SEC review), or pay 1% monthly liquidated damages capped at 5% of subscription amount.
Analysis · BMRA · Life Sciences
A $2.23 million private placement at $1.60 per share closed on August 26, 2026, with 1,393,705 shares sold to institutional and insider purchasers including B. Riley Principal Capital. The agreement grants B. Riley the right to designate one board member while it holds at least 10% voting power, and imposes 180-day lock-ups on directors and certain executives. For a company facing a going-concern warning and declining revenue, this capital extends runway but adds meaningful dilution and hands a strategic investor board-level influence.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1996 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRA was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.45 to $3.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.